



Powered by

**Lexaria**  
BIOSCIENCE

## Company Overview

Lexaria Bioscience Corp. (CSE:LXX; NASDAQ:LEXX) is a research-driven company that has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes faster delivery of drugs into the bloodstream, healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria's DehydraTECH technology is covered by issued and pending patents in over 40 countries around the world. Lexaria's first patent was issued by USPTO in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Collaborative research agreement with the National Research Council (NRC), the Canadian government's premier research and technology organization. Lexaria has filed for patent protection for delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors, tobacco and more.

In 2020, Lexaria's most urgent investigations are related to applying DehydraTECH to existing antiviral and other drugs that may be useful in the fight against Coronavirus.

Lexaria's technology has been thoroughly evaluated through in vivo, in vitro, and human clinical testing. Liquid chromatography high-resolution mass spectrometry, nuclear magnetic resonance, Fourier transform infrared ("FTIR") spectroscopy and other evaluatory processes have been used to characterize and study the transformative Lexaria technology.

## Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of \$9.6 Million Upsized Public Offering

Jan 12 2021, 7:00 AM EST

## Lexaria Announces Effective Date for Reverse Stock Split

Jan 8 2021, 4:45 PM EST

## Investor Relations

IR contact

T: 1-866-221-3341

[IR@lexariabioscience.com](mailto:IR@lexariabioscience.com)

## Management Team

### Chris Bunka

Chairman & CEO

### John Docherty

President and Director

### Allan Spissinger

CFO & Corporate Secretary

## Lexaria Bioscience Corp.

740 McCurdy Road  
Suite 100  
Kelowna, BC V1X 2P7  
Canada

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.